insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

MAIA · Maia Biotechnology, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · MAIA

1Y3YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$43.7K-$2.67M$3.11M$3.20M-$2.67M$2.05M$2.32M-
SG&A$3.42M-$3.00M$2.06M$2.23M-$1.52M$1.76M$1.63M-
Total Operating Expenses$6.95M-$9.36M$5.17M$5.43M-$4.19M$3.82M$3.95M-
D&A----------
Operating Income($6.95M)-($9.36M)($5.17M)($5.43M)-($4.19M)($3.82M)($3.95M)-
Interest Expense------$85---
Income Tax$339---$0---$0-
Net Income($6.37M)-($8.90M)($8.88M)($4.52M)-($2.74M)($8.88M)($8.07M)-
EPS - Basic($0.14)-($0.27)($0.18)($0.16)-($0.11)($0.40)($0.46)-
EPS - Diluted($0.14)-($0.27)($0.18)($0.16)-($0.11)($0.40)($0.46)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$0$0$0$0$0$0$0$0$0$0
Accounts Receivable----------
Inventory----------
Accounts Payable$2.98M$2.04M$3.18M$1.72M$1.84M$1.51M$1.15M$1.26M$1.87M$1.64M
Current Assets$35.32M$9.70M$11.75M$11.04M$11.86M$10.15M$9.24M$12.02M$8.70M$7.56M
Total Assets$35.32M$9.70M$11.78M$11.05M$11.86M$10.16M$9.24M$12.02M$8.72M$7.57M
Current Liabilities$6.32M$5.84M$9.99M$5.04M$5.06M$3.83M$3.61M$3.51M$4.91M$4.94M
Long-term Debt----------
Total Liabilities$7.56M$7.33M$11.74M$7.17M$6.92M$6.52M$7.62M$8.86M$14.48M$7.09M
Stockholders' Equity$27.76M$2.38M$41.7K$477.5K$4.94M$3.63M$1.62M$3.16M($5.76M)$477.5K
Retained Earnings($116.00M)($109.63M)($106.00M)($97.10M)($91.75M)($87.23M)($83.66M)($80.93M)($72.05M)($63.98M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($5.31M)---($4.20M)---($3.59M)-
Investing Cash Flow----------
Financing Cash Flow$31.05M---$5.46M---$4.72M-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-18.0%--75.6%-80.4%-38.1%--29.6%-73.9%-92.6%-
Return on equity-22.9%--21365.9%-1859.5%-91.4%--169.0%-280.8%139.9%-
Return on invested capital----------
Liquidity
Current ratio5.591.661.182.192.352.652.563.421.771.53
Quick ratio5.591.661.182.192.352.652.563.421.771.53
Cash ratio0.000.000.000.000.000.000.000.000.000.00
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage-------49276.1x---
Equity multiplier1.274.08282.7523.132.402.795.713.80-1.5115.85
Liabilities / Assets0.210.761.000.650.580.640.820.741.660.94
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B2.3x-1227.0x114.2x8.6x-41.5x24.0x--
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-28.1%--123.5%-35.4%-37.4%-15.5%-10.8%5.6%-
Net income growth (YoY)-41.0%--225.4%0.0%44.0%-43.9%-96.3%-108.8%-
EPS growth (YoY)12.5%--145.5%55.0%65.2%-69.4%-14.3%-21.1%-
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)461.7%-34.6%-97.4%-84.9%-661.2%-41.1%-54.0%--94.4%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing MAIA Biotechnology against the 5 most active filers in the same SIC group.